2.3(top 20%)
impact factor
1.6K(top 10%)
papers
21.5K(top 10%)
citations
56(top 10%)
h-index
2.4(top 20%)
impact factor
1.7K
all documents
21.9K
doc citations
72(top 20%)
g-index

Top Articles

#TitleJournalYearCitations
1Angiogenesis, neurogenesis and brain recovery of function following injuryCurrent Opinion in Investigational Drugs2010182
2Artemisinins for schistosomiasis and beyondCurrent Opinion in Investigational Drugs2007145
3Autophagy inhibition in combination cancer treatmentCurrent Opinion in Investigational Drugs2009127
4Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeuticsCurrent Opinion in Investigational Drugs2009120
5The modulatory role of melatonin on immune responsivenessCurrent Opinion in Investigational Drugs2006110
6Candida biofilms: antifungal resistance and emerging therapeutic optionsCurrent Opinion in Investigational Drugs2004103
7Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitisCurrent Opinion in Investigational Drugs200999
8Angiotensin II as a pro-inflammatory mediatorCurrent Opinion in Investigational Drugs200299
9RAGE in inflammation: a new therapeutic target?Current Opinion in Investigational Drugs200694
10Hyperthermia as an immunotherapy strategy for cancerCurrent Opinion in Investigational Drugs200992
11Multimodal analgesia: its role in preventing postoperative painCurrent Opinion in Investigational Drugs200892
12Sirtuins: novel targets for metabolic diseaseCurrent Opinion in Investigational Drugs200892
13FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levelsCurrent Opinion in Investigational Drugs201092
14The endocannabinoid system: a drug discovery perspectiveCurrent Opinion in Investigational Drugs200591
15Neurobiological mechanisms of addiction: focus on corticotropin-releasing factorCurrent Opinion in Investigational Drugs201090
16Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinicCurrent Opinion in Investigational Drugs200290
17Mitotane for adrenocortical carcinoma treatmentCurrent Opinion in Investigational Drugs200590
18Neuroimmune interactions and pain: focus on glial-modulating targetsCurrent Opinion in Investigational Drugs200885
19Regenerative medicine through mesenchymal stem cells for bone and cartilage repairCurrent Opinion in Investigational Drugs200279
20Bacteriophage therapy for the treatment of infectionsCurrent Opinion in Investigational Drugs200979
21Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinasesCurrent Opinion in Investigational Drugs201075
22The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectivesCurrent Opinion in Investigational Drugs201073
23New strategies for the treatment of infections associated with prosthetic jointsCurrent Opinion in Investigational Drugs200572
24STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancerCurrent Opinion in Investigational Drugs201072
25Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathwayCurrent Opinion in Investigational Drugs200470
26The pleuromutilin antibiotics: a new class for human useCurrent Opinion in Investigational Drugs201069
27Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotidesCurrent Opinion in Investigational Drugs200168
28COX-2 inhibitors as antidepressants and antipsychotics: clinical evidenceCurrent Opinion in Investigational Drugs201067
29Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depressionCurrent Opinion in Investigational Drugs200966
30PPARbeta/delta ligands as modulators of the inflammatory responseCurrent Opinion in Investigational Drugs200866
31Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancerCurrent Opinion in Investigational Drugs200966
32Fatty acid biosynthesis as a target for novel antibacterialsCurrent Opinion in Investigational Drugs200465
33Corticotropin-releasing hormone modulators and depressionCurrent Opinion in Investigational Drugs200365
34Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophreniaCurrent Opinion in Investigational Drugs200765
35Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapyCurrent Opinion in Investigational Drugs200865
36Autoimmunity in autismCurrent Opinion in Investigational Drugs200964
37Experimental therapeutics: targeting the redox Achilles heel of cancerCurrent Opinion in Investigational Drugs200764
38BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumorsCurrent Opinion in Investigational Drugs200864
39FGF21: a novel prospect for the treatment of metabolic diseasesCurrent Opinion in Investigational Drugs200964
40The impact of carbapenemases on antimicrobial development and therapyCurrent Opinion in Investigational Drugs200263
41Mitogen-activated protein kinases as potential targets for pain killersCurrent Opinion in Investigational Drugs200463
42The road to licensure of a DNA vaccineCurrent Opinion in Investigational Drugs200763
43The development of nanobodies for therapeutic applicationsCurrent Opinion in Investigational Drugs200963
44Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogeneticsCurrent Opinion in Investigational Drugs201063
45CD200 and its receptors as targets for immunoregulationCurrent Opinion in Investigational Drugs200562
46MicroRNAs: small but potent oncogenes or tumor suppressorsCurrent Opinion in Investigational Drugs200662
47Diamidines as antitrypanosomal, antileishmanial and antimalarial agentsCurrent Opinion in Investigational Drugs200661
48Diamidines for human African trypanosomiasisCurrent Opinion in Investigational Drugs201061
49ABC transporters and inhibitors: new targets, new agentsCurrent Opinion in Investigational Drugs200260
50Therapeutic potential of neuronal two-pore domain potassium-channel modulatorsCurrent Opinion in Investigational Drugs200760